Molecular characterization of the rare translocation t(3;10)(q26;q21) in an acute myeloid leukemia patient

JANCUSKOVA, T, R PLACHY, L ZEMANKOVA, DW HARDEKOPF, Jiří ŠTIKA, L ZEJSKOVA, I PRAULICH, KA KREUZER, A ROTHE, MAK OTHMAN, N KOSYAKOVA a S PEKOVA. Molecular characterization of the rare translocation t(3;10)(q26;q21) in an acute myeloid leukemia patient. MOLECULAR CYTOGENETICS. LONDON: BioMed Central, 2014, roč. 7, 5 s. ISSN 1755-8166. Dostupné z: https://dx.doi.org/10.1186/1755-8166-7-47.

Základní údaje

• Originální název: Molecular characterization of the rare translocation t(3;10)(q26;q21) in an acute myeloid leukemia patient
• Autoři: JANCUSKOVA, T, R PLACHY, L ZEMANKOVA, DW HARDEKOPF, Jiří ŠTIKA, L ZEJSKOVA, I PRAULICH, KA KREUZER, A ROTHE, MAK OTHMAN, N KOSYAKOVA a S PEKOVA.
• Vydání: MOLECULAR CYTOGENETICS, LONDON, BioMed Central, 2014, 1755-8166.

Další údaje

• Originální jazyk: angličtina
• Typ výsledku: Článek v odborném periodiku
• Utajení: není předmětem státního či obchodního tajemství
• Impakt faktor: Impact factor: 2.140
• Doi: http://dx.doi.org/10.1186/1755-8166-7-47
• UT WoS: 000339521000001
• Klíčová slova anglicky: AML; MECOM; Chromosomal microdissection; Next-generation sequencing; Molecular marker
• Příznaky: Mezinárodní význam, Recenzováno

Anotace

Background: In acute myeloid leukemia (AML), the MDS1 and EVI1 complex locus - MECOM, also known as the ecotropic virus integration site 1 - EVI1, located in band 3q26, can be rearranged with a variety of partner chromosomes and partner genes. Here we report on a 57-year-old female with AML who presented with the rare translocation t(3;10) (q26;q21) involving the MECOM gene. Our aim was to identify the fusion partner on chromosome 10q21 and to characterize the precise nucleotide sequence of the chromosomal breakpoint. Methods: Cytogenetic and molecular-cytogenetic techniques, chromosome microdissection, next generation sequencing, long-range PCR and direct Sanger sequencing were used to map the chromosomal translocation. Results: Using a combination of cytogenetic and molecular approaches, we mapped the t(3;10)(q26;q21) to the single nucleotide level, revealing a fusion of the MECOM gene (3q26.2) and C10orf107 (10q21.2). Conclusions: The approach described here opens up new possibilities in characterizing acquired as well as congenital chromosomal aberrations. In addition, DNA sequences of chromosomal breakpoints may be a useful tool for unique molecular minimal residual disease target identification in acute leukemia patients.